<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15597">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903836</url>
  </required_header>
  <id_info>
    <org_study_id>W-4873-201</org_study_id>
    <nct_id>NCT02903836</nct_id>
  </id_info>
  <brief_title>Phase II Study of Oral Nafithromycin in CABP</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ACM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wockhardt</source>
  <brief_summary>
    <textblock>
      Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral
      Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial
      Pneumonia (CABP) in Adults
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response in the ITT population</measure>
    <time_frame>day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response in the micro-ITT population</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation is based on number of subjects with TEAEs,abnormal clinical laboratory evaluation, abnormal vital signs, abnormal physical examination findings and abnormal ECGs during the treatment and follow up phase.</measure>
    <time_frame>31 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Community-Acquired Bacterial Pneumonia (CABP)</condition>
  <arm_group>
    <arm_group_label>Nafithromycin 800 mg 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO q24h for 3 days; subjects will receive matching placebo , to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nafithromycin 800 mg 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO q24h for 5 days; subjects will receive matching placebo, to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO q24h for 7 days;subjects will also receive two nafithromycin placebo tablets PO q24h on Days 1 through Day 7 to maintain the blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nafithromycin 800 mg 3 days</intervention_name>
    <arm_group_label>Nafithromycin 800 mg 3 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nafithromycin 800 mg 5 days</intervention_name>
    <arm_group_label>Nafithromycin 800 mg 5 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400 mg</intervention_name>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Meet the clinical criteria for CABP based on following:

          1. Clinical symptoms (new or worsening)

          2. Vital sign abnormalities

          3. Laboratory abnormalities

          4. Radiographic evidence of CABP

          5. PORT score

        Exclusion Criteria:

          1. Subjects with any of the following confirmed or suspected types of pneumonia:

               1. Aspiration pneumonia

               2. Hospital-acquired bacterial pneumonia (HABP)

               3. Healthcare-associated bacterial pneumonia (HCAP)

               4. Ventilator-associated bacterial pneumonia (VABP)

               5. Pneumonia that may be caused by pathogen(s) resistant to either study drug

          2. Receipt of 1 or more dose(s) of a potentially effective systemic antibacterial
             treatment for treatment of the current CABP

          3. Suspected or confirmed non-infectious causes of pulmonary infiltrates

          4. Subjects requiring concomitant adjunctive or additional potentially-effective
             systemic antibacterial treatment for management of CABP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashima Bhatia, MD PDCR</last_name>
    <role>Study Director</role>
    <affiliation>Wockhardt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rakesh Chugh, MD</last_name>
    <phone>91-22-7159 6833</phone>
    <email>rchugh@wockhardt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashima Bhatia, MD PDCR</last_name>
    <phone>91-22-7159 6830</phone>
    <email>abhatia@wockhardt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Empire Clinical Research, LLC</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Ricardo-Colomar, Medical Doctor</last_name>
      <email>salv.chamizo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chamizo Salvador</last_name>
      <email>salv.chamizo@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>A &amp; L Clinical research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Barrera, Medical Doctor</last_name>
      <email>AMuMartin19@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Murcia-Martin</last_name>
      <email>AMuMartin19@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>A Plus Research Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hector Labrada, Medical Doctor</last_name>
      <phone>+305 (229) 4053</phone>
      <email>niurka@aplusresearch.co</email>
    </contact>
    <contact_backup>
      <phone>+305 (229) 4053</phone>
      <email>niurka@aplusresearch.co</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>RM Medical Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Delgado, Medical Doctor</last_name>
      <phone>+1 (954) 243 1181</phone>
      <email>director@newamericanresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Jorge Presas</last_name>
      <phone>+1 (954) 243 1181</phone>
      <email>director@newamericanresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HCI Metromedic Walkin Medical Center</name>
      <address>
        <city>Bedford</city>
        <state>Massachusetts</state>
        <zip>02740-6634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tushar Patel, Medical Doctor</last_name>
      <phone>+1 (508) 997 2900</phone>
      <email>jennyquenn@hotmail.com</email>
    </contact>
    <contact_backup>
      <phone>+1 (508) 997 2900</phone>
      <email>jennyquenn@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Bedford</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Beasley, Medical Doctor</last_name>
      <phone>+605 (721) 5038</phone>
      <email>martyandkelly@rap.midco.net</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Beasley</last_name>
      <phone>+605 (721) 5038</phone>
      <email>martyandkelly@rap.midco.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>September 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
